2014-01-21 20:18:02 -
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, has entered into a business relationship with Therakos, Inc., a global leader in advancing the science of extracorporeal photopheresis (ECP), to be the exclusive distributor in Australia and New Zealand of the THERAKOS® UVAR XTS® Photopheresis System (XTS) and the THERAKOS® CELLEX® Photopheresis System (Cellex), which physicians use to treat patients with diseases of the immune system.
Through its relationship with Therakos, Terumo BCT will be able to expand its product portfolio to provide customers with broader therapeutic products and protocols.
- THERAKOS® Photopheresis Systems are the only integrated systems for ECP, a leukapheresis-based immunomodulatory therapy that has been approved by the U.S. Food and Drug Administration for
the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma unresponsive to other forms of treatment
- On average more than 1,200 ECP procedures are performed each year in Australia
- Terumo BCT has signed an exclusive multi-year agreement to distribute Therakos products in Australia and New Zealand
- Terumo BCT is the leading supplier of apheresis technology in the region
- Terumo BCT will begin distributing Therakos products in mid-January 2014
Bob Sullivan, Vice President, Therapeutic Systems, Terumo BCT
“Our business relationship with Therakos complements our existing apheresis expertise and product offerings while expanding our immunology therapeutic product offering to enable us to provide our customers with state-of-the-art ECP products. Through our relationship we will be able to provide an even broader range of therapeutic products and protocols to further advance our position as a market leader.”
Sandra Thompson, Chief Operating Officer, Therakos
“The establishment of the strategic relationship with Terumo BCT is an important milestone for Therakos and our global expansion strategy.
Bringing together the Therakos clinical experience with the market presence and infrastructure of Terumo BCT in Australia and New Zealand will provide for greater access and treatment options for patients."
About Therakos Inc.:
Therakos, Inc : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww ..
. is the global leader in the science of extracorporeal photopheresis, an immune cell therapy. Therakos, Inc. has developed and marketed the only integrated systems for ECP for over 25 years. Therakos is committed to advancing the science of ECP and serving scientists, physicians, and the patients who suffer from a variety of debilitating immune-based diseases. For additional information on Therakos’ products and their approved indications, please visit: www.therakos.com : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww ..
About Terumo BCT:
Terumo BCT : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbit ..
, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
" title="http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140121006567r1&sid=16929&distro=ftp\"/>" target="_blank" rel="nofollow">cts.businesswire.com/ct/CT?id=bwnews&sty=20140121006567r1&am ..
Terumo BCTLaura Fusco, +1-303-205-2546Global Corporate